Treatment with Tyrosine Kinase Inhibitors

摘要: Leukemias have traditionally served as model systems for research on neoplasia because of the easy availability cell material from blood and marrow diagnosis, monitoring, studies pathophysiology. Beyond these more technical aspects, chronic myeloid leukemia (CML) became first in which elucidation genotype led to a rationally designed therapy phenotype. Targeting pathogenetically relevant Bcr-Abl tyrosine kinase with inhibitor imatinib has induced remissions almost complete disappearance any signs symptoms CML. This therapeutic success triggered an intensive search suitable targets other cancers development numerous inhibitors potential now being studied preclinical clinical trials worldwide. Imatinib mesylate been selective employed patients. Its routine use considered revolution treatment